Trastuzumab in metastatic breast cancer

F. Tomao; E. Miele; G. P. Spinelli; M. Russillo; G. La Ferla; S. Tomao

Trastuzumab in metastatic breast cancer

F. Tomao, E. Miele, G. P. Spinelli, M. Russillo, G. La Ferla, S. Tomao

Istituto Europeo di Oncologia

Research output: Contribution to journal › Article

Abstract

Metastatic breast cancer is an incurable disease in a very high percentage of patients. Despite new progress in endocrine and other systemic therapies, this evidence remains challenging for patients and clinicians. HER2 protein is a member of the epidermal growth factor family of transmembrane receptors. HER2 is overexpressed in approximately 20% to 30% of breast cancers. Overexpression of HER2 has been shown to be associated with increased tumor proliferation and relative resistance to some types of chemotherapy and hormonal therapies. Trastuzumab, a humanized monoclonal antibody directed against HER2 protein, has been shown to be an efficacious and well tolerated treatment for HER2-overexpressing metastatic breast cancer, both as a single agent and when it is used in combination with chemotherapy.

Original language	English
Pages (from-to)	247-249
Number of pages	3
Journal	European Journal of Gynaecological Oncology
Volume	27
Issue number	3
Publication status	Published - 2006

Keywords

HER2
Metastatic breast cancer
Trastuzumab

ASJC Scopus subject areas

Obstetrics and Gynaecology
Oncology

Access to Document

Fingerprint Dive into the research topics of 'Trastuzumab in metastatic breast cancer'. Together they form a unique fingerprint.

Cite this

Tomao, F., Miele, E., Spinelli, G. P., Russillo, M., La Ferla, G., & Tomao, S. (2006). Trastuzumab in metastatic breast cancer. European Journal of Gynaecological Oncology, 27(3), 247-249.

@article{7e8faccd32a543d088d2b08f2f79ab40,

title = "Trastuzumab in metastatic breast cancer",

abstract = "Metastatic breast cancer is an incurable disease in a very high percentage of patients. Despite new progress in endocrine and other systemic therapies, this evidence remains challenging for patients and clinicians. HER2 protein is a member of the epidermal growth factor family of transmembrane receptors. HER2 is overexpressed in approximately 20% to 30% of breast cancers. Overexpression of HER2 has been shown to be associated with increased tumor proliferation and relative resistance to some types of chemotherapy and hormonal therapies. Trastuzumab, a humanized monoclonal antibody directed against HER2 protein, has been shown to be an efficacious and well tolerated treatment for HER2-overexpressing metastatic breast cancer, both as a single agent and when it is used in combination with chemotherapy.",

keywords = "HER2, Metastatic breast cancer, Trastuzumab",

author = "F. Tomao and E. Miele and Spinelli, {G. P.} and M. Russillo and {La Ferla}, G. and S. Tomao",

year = "2006",

language = "English",

volume = "27",

pages = "247--249",

journal = "European Journal of Gynaecological Oncology",

issn = "0392-2936",

publisher = "S.O.G. CANADA Inc.",

number = "3",

}

TY - JOUR

T1 - Trastuzumab in metastatic breast cancer

AU - Tomao, F.

AU - Miele, E.

AU - Spinelli, G. P.

AU - Russillo, M.

AU - La Ferla, G.

AU - Tomao, S.

PY - 2006

Y1 - 2006

N2 - Metastatic breast cancer is an incurable disease in a very high percentage of patients. Despite new progress in endocrine and other systemic therapies, this evidence remains challenging for patients and clinicians. HER2 protein is a member of the epidermal growth factor family of transmembrane receptors. HER2 is overexpressed in approximately 20% to 30% of breast cancers. Overexpression of HER2 has been shown to be associated with increased tumor proliferation and relative resistance to some types of chemotherapy and hormonal therapies. Trastuzumab, a humanized monoclonal antibody directed against HER2 protein, has been shown to be an efficacious and well tolerated treatment for HER2-overexpressing metastatic breast cancer, both as a single agent and when it is used in combination with chemotherapy.

AB - Metastatic breast cancer is an incurable disease in a very high percentage of patients. Despite new progress in endocrine and other systemic therapies, this evidence remains challenging for patients and clinicians. HER2 protein is a member of the epidermal growth factor family of transmembrane receptors. HER2 is overexpressed in approximately 20% to 30% of breast cancers. Overexpression of HER2 has been shown to be associated with increased tumor proliferation and relative resistance to some types of chemotherapy and hormonal therapies. Trastuzumab, a humanized monoclonal antibody directed against HER2 protein, has been shown to be an efficacious and well tolerated treatment for HER2-overexpressing metastatic breast cancer, both as a single agent and when it is used in combination with chemotherapy.

KW - HER2

KW - Metastatic breast cancer

KW - Trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=33745458662&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745458662&partnerID=8YFLogxK

M3 - Article

C2 - 16800251

AN - SCOPUS:33745458662

VL - 27

SP - 247

EP - 249

JO - European Journal of Gynaecological Oncology

JF - European Journal of Gynaecological Oncology

SN - 0392-2936

IS - 3

ER -